MedPath

Vibrational Therapy to Improve Gait and Balance in Parkinson's Disease

Not Applicable
Withdrawn
Conditions
Parkinson Disease
Interventions
Device: PDVibe2
Registration Number
NCT03872115
Lead Sponsor
Virginia Commonwealth University
Brief Summary

The purpose of this research study is to determine optimum dose of vibration delivered by an experimental device called PDVibe2 required to treat freezing of gait in persons with Parkinson's disease (PD). The PDVibe2 was developed by Resonate Forward, LLC (RF). This PDVibe2 was designed to administer vibration therapy to the wearer to improve gait and balance in persons with PD while wearing the device.

Detailed Description

Participation will require up to 8 treatment sessions within 5 days (no more than 2 sessions in one day) plus an additional day for screening and another for follow-up (7 days total). All visits will occur at the Virginia Commonwealth University Parkinson's Movement and Disorders Center in Richmond, VA. Participants will be asked to walk for a brief period of time while wearing the PDVibe2. The PDVibe2 will provide vibration therapy and study staff will measure the number of "freezes" before, during and after therapy. Participants will be asked to provide feedback on the device, the therapy session and how they are feeling.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria
  • diagnosed with a known Parkinson plus syndrome
  • were previously exposed to vibration treatment for gait and balance
  • presence of dementia (Montreal Cognitive Assessment < 21)
  • additional disorders (not related to PD)impairing gait, stance, balance or coordination (e.g. stroke, leg amputations, or multiple sclerosis)
  • history of implantable cardiac device or any other implanted electronic device except a deep brain stimulator (DBS)
  • use of braces/orthotics that assist with walking
  • are currently in physical therapy (PT) treatment for balance or gait
  • peripheral neuropathy by exam
  • any condition that, in the opinion of the PIs, would compromise participant safety, data integrity, or data interpretation.
  • Children under the age of 18
  • Prisoners
  • Women who are pregnant or may become pregnant during the course of this study since the safety of this device for an unborn child is unknown.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Setting 5PDVibe2PDVibe2 set to medium frequency and medium amplitude
Setting 1PDVibe2PDVibe2 set to high frequency and low amplitude
Setting 2PDVibe2PDVibe2 set to high frequency and medium amplitude
Setting 7PDVibe2PDVibe2 set to low frequency and low amplitude
Setting 3PDVibe2PDVibe2 set to high frequency and high amplitude
Setting 4PDVibe2PDVibe2 set to medium frequency and low amplitude
Setting 8PDVibe2PDVibe2 set to low frequency and medium amplitude
Setting 6PDVibe2PDVibe2 set to medium frequency and high amplitude
Setting 9PDVibe2PDVibe2 set to low frequency and high amplitude
Primary Outcome Measures
NameTimeMethod
Functional Ambulation Profile (FAP) ScoreThroughout study completion, from 9 to 34 days.

The FAP score is the gold standard for spatiotemporal gait parameter analysis. For this study, it will be calculated by participants walking on the Zeno walkway, which will measure the patient's physical measurements, step length, step time and degree of symmetry.Step length, step time, degree of symmetry, dynamic base of support and the use of ambulatory aids are factored into the score. The Zeno instrumented walkway (PKMAS) is a 20-foot computerized instrumented walkway containing sensor pads.

Secondary Outcome Measures
NameTimeMethod
Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part IIIThroughout study completion, between 9 to 34 days.

The "Movement Disorder Society Unified Parkinson Disease Rating Scale" (MDS-UPDRS), parts II-IV will be used to assess the total burden of motor Parkinson Disease (PD) symptoms and impact on activities of daily living. All parts use scale of 0 (no problem) - 4 (severe problems) lower scores are better. Part II: 13 items about Activities of Daily Living, score range 0-52. Part III: 18 items PD motor signs, score range is 0-72, Part IV: 6 items, assesses dyskinesia (excessive motion) and motor fluctuations (medication is working or not), range is 0-24. Parts II-IV total scores will be summed and used to describe the participants, total score range 0-148. Part III, only, will be repeated during vibration and post vibration data collection times and will take 5 minutes to complete. This outcome measure will be used to report a change in PD motor symptoms from baseline, to vibration on, and at follow up two after treatment is completed.

Berg Balance ScaleThroughout study completion, between 9 to 34 days.

The BBS assesses balance via performing 14 functional activities. Each item is scored along a 5-point scale, ranging from 0 to 4. Zero indicates the lowest level of function and 4 the highest level of function. The total score is a summation of all items and ranges from 0 to 56. Higher scores indicate less risk of falls. A cutoff score of 45 has been traditionally identified as a useful cutoff to predict falls in those who scored below the cutoff score.

Freezing of Gait QuestionnaireThroughout study completion, between 9 to 34 days

The FOG-Q is a six-item questionnaire that uses a 5-point scale that ranges from 0 = absence of symptoms to 4 = most severe stage. The total score ranges from 0 to 24; higher scores correspond to more severe FOG.

Fall Efficacy Scale - InternationalThroughout study completion, between 9 to 34 days.

This survey includes 16 items assessing fear of falling in different scenarios, in a community dwelling older population. Individuals are instructed to rate each activity on a four-point Likert scale, depending on how they concerned that they may fall when performing certain activities. Items are scored from 1 = Not at all concerned to 4 = very concerned. The total score ranges from 16 - 64. The higher the score the greater the fear of falling.

Timed Up and Go TestThroughout study completion, between 9 to 34 days.

This test is a one item performance test. The participant starts by sitting in a chair, then stand up, walk 3 meters, turn around, walk back, and sit down. Participants are timed in seconds. TUG is used to identify/screen elderly individuals who are prone to falls. Lower numbers are better.

Parkinson's Disease Questionnaire - 39Throughout study completion, between 9 to 34 days.

This is a 39 item self-report questionnaire assesses how often patients experience difficulties across the 8 quality of life dimensions of functioning and well-being. A five-point ordinal scoring system ranges from 0 Never to 5 = Always or cannot do at all. Scores are calculated for each dimension (sum of items divided by number of items /100; total score is summative

Trial Locations

Locations (1)

Virginia Commonwealth University

🇺🇸

Richmond, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath